(AOF) – Biotech Hybrigenics details in a press release the activities of B Cell Design, a biotechnology company developing artificial immunoglobulins (antibodies), acquired in November 2021, through its subsidiary Inoviem Scientific. This acquisition aimed to complete the subsidiary’s value chain and increase the group’s market share. The originality of B Cell Design’s technological approach is based on its ability to produce human chimeric antibodies directly in animals, which gives the company a technological lead over its competitors.
In accordance with the group’s development plan, the strategic and industrial approach to this activity has been transformed by initially positioning the B Cell Design offer on the diagnostics market in order to become the leader in raw materials of synthetic origin on the classic immunoassay segment (Elisa and Dot) or new generation (immunofluorescence: Clia).
To do this, the company has accelerated its industrialization by setting up a bioproduction laboratory on the Alsatian site of Illkirch in order to increase its production. Hybrigenics now plans to duplicate this model directly in the United States and China, closer to its main markets.
The global antibody market represents a total amount of around 100 billion euros and is growing at a rapid annual rate of more than 20% over the past few years.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.